New drug cocktail aims to spare bladders in aggressive cancer
NCT ID NCT07151560
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study tests whether combining two drugs (disitamab vedotin and toripalimab) can help people with a certain type of advanced bladder cancer (HER2-positive) avoid bladder removal. About 60 adults with muscle-invasive bladder cancer that hasn't spread will receive the treatment. The main goal is to see how many remain cancer-free with their bladder intact after one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROLOGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.